Making a difference with your help.
Protocol Name: Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis Protocol #: 20220159 Indication: ANCA associated Vasculitis GFR: ≥15 Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure Protocol #: D6972C00002 Indication: CKD & HTN GFR: 30-75 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease Protocol #: D6800C00005 Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥ 25 Principal Investigator: Akinwande Akinfolarin Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Protocol #: EASi-Kidney Indication: CKD GFR: 20-90 DETAILS >
Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Protocol #: D6972C00003 Indication: CKD & HTN GFR: 30-89 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Protocol #: VX24-147-202 Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 to ≤75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Protocol #: AIS-D08 RANIER Indication: IgA Nephropathy GFR: ≥30 DETAILS >
Protocol Name: Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy Protocol #: Nef-403 (NefXtend) Indication: IgA Nephropathy DETAILS >
Protocol Name: Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study (Improving Shared Decision-Making and Access to Non-Dialytic Treatment for People with Kidney Disease) Protocol #: PCORI ExPAND Indication: Late Stage CKD GFR: <20 DETAILS >
Protocol Name: Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/- V Protocol #: CLNP023K12201 Indication: Lupus Nephritis GFR: ≥ 25 DETAILS >